Wall Street analyst estimates for BioAtla, Inc. (BCAB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (1-5) | 0.67 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-7.00 | ||
| 2026-08-13 | $0.27 | $-8.50 | +103.2% |
| 2026-05-15 | $-6.18 | $-10.00 | +38.2% |
| 2026-03-31 | $-8.00 | $-12.00 | +33.3% |
| 2025-11-13 | $-13.50 | $-0.31 | -4254.8% |
| 2025-08-07 | $-16.00 | $-0.29 | -5354.6% |
| 2025-05-06 | $-13.00 | $-0.29 | -4331.9% |
| 2025-03-27 | $-15.00 | $-0.40 | -3650.0% |
Valuation Ratios
| Price / Book | -0.08 |
| EV / EBITDA | -0.25 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.6M | $5.2M | $429000 | $250000 | 0 | 0 | $11.0M | $2.0M |
| Cost of Revenue | $26.3M | $25.9M | $19.9M | $58.3M | $1.2M | $1.2M | $925000 | $43.1M |
| Gross Profit | -$15.7M | -$20.7M | -$19.5M | -$58.0M | -$1.2M | -$1.2M | $10.1M | -$41.1M |
| Research & Development | $26.3M | $25.9M | $19.9M | $58.3M | $79.3M | $103.7M | $63.1M | $43.6M |
| Selling, General & Admin | $12.6M | $7.5M | $10.6M | $38.4M | $28.8M | $26.0M | $21.8M | $17.6M |
| Operating Expenses | $38.9M | $7.5M | $10.6M | $38.4M | $106.9M | $128.5M | $84.0M | $18.2M |
| Operating Income | -$28.2M | -$28.3M | -$30.1M | -$96.4M | -$108.1M | -$129.7M | -$73.9M | -$59.3M |
| EBITDA | -$27.2M | -$27.4M | -$33.5M | -$94.1M | -$105.3M | -$122.2M | -$68.9M | -$59.2M |
| Interest Expense | $949000 | $1.6M | $1.4M | $3000 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$29.0M | -$29.9M | -$35.9M | -$95.4M | -$106.5M | -$123.5M | -$69.8M | -$59.6M |
| Income Tax | $204000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$29.0M | -$29.8M | -$35.9M | -$95.4M | -$105.3M | -$123.5M | -$69.8M | -$59.6M |
| EPS | $-67.00 | $-46.50 | $-53.00 | $-138.00 | $-137.00 | $-129.00 | $-72.00 | $-50.50 |
| EPS (Diluted) | $-67.00 | $-46.50 | $-53.00 | $-138.00 | $-137.00 | $-129.00 | $-72.00 | $-50.50 |
| Shares Outstanding (Diluted) | $431772 | $673272 | $673272 | $691225 | $778545 | $955551 | $971467 | $1.2M |
Price
| Price | $1.74 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANVS · BTAI · CELU · EVAX · GBIO · MRSN · MURA
Explore sector: Healthcare · Biotechnology
More sections of BCAB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks